J Biol Chem, Vol. 275, Issue 2, 1279-1286, January 14, 2000
Identification of a Novel Eosinophil Chemotactic Cytokine
(ECF-L) as a Chitinase Family Protein*
Makoto
Owhashi
,
Hiroyuki
Arita, and
Naoko
Hayai
From the Faculty of Integrated Arts and Sciences, Tokushima
University, Tokushima 770-8502, Japan
 |
ABSTRACT |
A novel eosinophil chemotactic cytokine (ECF-L)
was purified from the culture supernatant of splenocytes of mice by a
combination of anion-exchange chromatography, Procion red-agarose
affinity chromatography, size exclusion high performance liquid
chromatography (HPLC), and reverse phase HPLC. The
NH2-terminal amino acid sequence was determined by
direct protein sequencing. An ECF-L cDNA clone of 1,506 nucleotides
was isolated from a cDNA library, and the nucleotide sequence
predicted a mature protein of 397 amino acids. A recombinant ECF-L
showed a level of eosinophil chemotactic activity comparable with that
of natural ECF-L, and the activity was inhibited by a monoclonal
antibody to ECF-L. ECF-L also attracted T lymphocytes and bone marrow
polymorphonuclear leukocytes in vitro, whereas it caused
selective extravasation of eosinophils in vivo. ECF-L mRNA was highly expressed in spleen, bone marrow, lung, and heart. A comprehensive GenBank data base search revealed that ECF-L is a
chitinase family protein. ECF-L retains those amino acids highly conserved among chitinase family proteins, but Asp and Glu residues essential for the proton donation in hydrolysis were replaced by Asn
and Gln, respectively. Although ECF-L contains a consensus CXC sequence near the NH2 terminus akin to
chemokine family proteins, the rest of ECF-L shows poor homology with chemokines.
 |
INTRODUCTION |
Many parasites, especially tissue-invasive helminths, cause local
eosinophilia as well as systemic eosinophilia in mammalian hosts. For
example, Schistosoma mansoni (1) Schistosoma
japonicum (2), Toxocara canis (3), and
Mesocestoides corti (4) form eosinophilic inflammatory
lesions in host tissue at the site where they invade or lay their eggs.
The mechanisms by which eosinophils are recruited to local inflammatory
sites via the circulation have been elucidated at least in part using
eosinophil chemotactic factors
(ECFs)1 (5).
Increased eosinopoiesis in bone marrow is observed prior to the tissue
eosinophilia in parasitic infections (6, 7). Indeed, most multipotent
hemopoietic stem cells are located in bone marrow (8). On the other
hand, kinetic studies suggest that the spleen is the site where
eosinophils mature (9), indicating eosinophil influx from the bone
marrow to spleen at the maturation stage.
Previous studies have shown that a splenocyte-derived ECF (ECF-L) is
produced in an antigen-specific manner during the course of parasitic
infections accompanying systemic and local eosinophilia (7), and
CD4
CD8+ T cells play an important role in
ECF-L production (10). Although ECF-L can be discriminated from other
ECFs in terms of its physicochemical and immunochemical properties
(11), the molecular structure of ECF-L still remains unclear. To obtain
further insight into the immunological functions of ECF-L at the
molecular level, cloning of cDNA encoding ECF-L is needed.
In this paper, we present the isolation of cDNA encoding ECF-L, the
molecular expression of ECF-L, and a structure comparison of ECF-L with
related proteins. The results clearly show that ECF-L is a novel
eosinophil chemotactic cytokine that belongs to the chitinase protein family.
 |
EXPERIMENTAL PROCEDURES |
Mice and Infection--
Female C57BL/6 or ddY mice were obtained
from Japan SLC (Hamamastu, Japan) and used at 8-10 weeks of age. They
were infected intraperitoneally with 30 cercariae of S. japonicum (Japanese strain) or 100 tetrathyridiae of M. corti and were killed by cervical dislocation under ether anesthesia.
Antigens--
Soluble egg antigen of S. japonicum was
prepared as described previously (12). In short, the eggs were
harvested from the intestines of S. japonicum-infected mice
by enzymatic digestion using Pronase (Kaken, Tokyo, Japan) and
collagenase (type I, Sigma Chemical Co., St. Louis, MO). Eggs were
suspended in 5.8 mM phosphate-buffered saline (PBS, pH 7.4)
and homogenized with a Teflon homogenizer in an ice-chilled water bath.
The mixture was centrifuged at 100,000 × g for l h.
The supernatant was used as S. japonicum egg antigen. Purification of a major 260-kDa antigen (J1) was performed as described
previously (13). For preparation of soluble M. corti antigen, tetrathyridiae of M. corti were homogenized with a
Teflon homogenizer in an ice-chilled water bath and centrifuged at
100,000 × g for 30 min. The supernatant was used as
M. corti antigen.
Eosinophils, Neutrophils, or Macrophages--
For collection of
eosinophil-rich peritoneal exudate cells, ddY mice were infected
intraperitoneally with 100 larvae of M. corti. 3 weeks
later, peritoneal lavage was harvested. The cells were washed twice
with PBS and suspended in RPMI 1640 medium (Life Technologies, Inc.,
Grand Island, NY) containing 2% FBS (Life Technologies, Inc.). To
remove adherent cells, the cell suspension was incubated in a tissue
culture flask (Nunc) at 37 °C for 30 min. The nonadherent cells were
used for eosinophil chemotaxis experiments. By this method, more than
1 × 107 eosinophils were collected from one mouse,
and the purity of the eosinophils was 50-70%. Major contaminants were
macrophages and neutrophils. Neutrophil-rich or macrophage-rich
peritoneal exudate cells were obtained from normal ddY mice that
received an intraperitoneal injection of 2 ml of 0.1% oyster glycogen
(Nacalai Tesque, Kyoto, Japan) 2 h or 48 h before use, for
neutrophils or macrophages, respectively. Neutrophil-rich (>90%) or
macrophage-rich (40-50%) cell suspensions from three animals were
pooled and used for the respective chemotaxis experiments.
T Lymphocytes--
T lymphocytes for chemotaxis indicator cells
were prepared as a T cell line. Female C57BL/6 mice were immunized with
20 µg of ovalbumin (Sigma) in complete Freund's adjuvant. 12 days
later, the spleen was removed, ground to single cell suspensions, and washed twice with PBS. The splenocytes were cultured with 30 µg/ml OVA in RPMI 1640 containing 2% FBS. Blast cells were separated on a
Ficoll (Amersham Pharmacia Biotech) density gradient and then cultured
without antigen for 7 days in RPMI 1640 containing 2% FBS and 5% rat
growth factor (supernatant of rat splenocytes cultured with 1 µg/ml
concanavalin A in RPMI 1640 containing 2% FBS for 2 days). The cells
(5 × 105/ml) were restimulated with 10 µg/ml
ovalbumin in the presence of 5 × 106/ml irradiated
splenocytes. The blast cells were cultured in RPMI 1640 containing 2%
FBS and 5% rat growth factor for 7 days. After washing twice with PBS,
they were used for chemotaxis experiments.
Chemotaxis Assay--
Chemotactic activities in vitro
were measured as described previously (10) with slight modifications.
Briefly, multiwell microchemotaxis chambers (Neuro Probe, Bethesda, MD)
were equipped with Millipore membrane filters (Millipore Co., Bedford,
MA) with a pore size of 3 µm for eosinophil and neutrophil chemotaxis
or 8 µm for macrophage and T lymphocyte chemotaxis. The number of indicator cells was adjusted to 1 × 106/ml with RPMI
1640 medium containing 2% heat-inactivated FBS. Incubation was
performed at 37 °C for 1 h in neutrophil chemotaxis or for
2 h in eosinophil, macrophage, or T lymphocyte chemotaxis. The
membranes were stained according to Litt's procedure (51). The
indicator cells that migrated into the membrane were counted from a
fixed level from the upper surface down to the lower surface. The
distance from the upper surface was selected as a value between 60 and
90 µm from the upper surface to achieve background counts of less
than 20 cells/10 high power field at 400 x. The total number of
migrated cells was counted in 10 randomly selected high power fields.
The chemotaxis experiments were done in quadruplicate and repeated at
least twice. RANTES (Pepro Tech, London, U. K.), GRO (Diaclone
Research, Besamcom Cedex, France), or MCP-1 (R & D Systems,
Minneapolis, MN) was used as chemotaxis positive control.
In Vivo Study for Eosinophil Accumulation--
Samples (25 µl)
were injected intradermally on the back of ddY mice that had been
injected with 100 tetrathyridiae of M. corti 3 weeks
earlier. 2 h later, mice were sacrificed, and the injection sites
were collected. The tissue samples were fixed in 10% formalin, embedded in paraffin, sectioned at 4 µm, and stained with hematoxylin and eosin.
Preparation of Conditioned Medium--
The spleen was removed
from normal or S. japonicum-infected mice 8 weeks after
infection and gently squashed between two frost-ended slides in cold
Hanks' balanced salt solution. The cell suspensions were washed with
Hanks' balanced salt solution and suspended in serum-free RPMI 1640. Culturing was carried out at 37 °C for 24 h in a 5%
CO2 and air environment in the presence of
purified egg antigen J1 (10 µg/ml). Conditioned medium was obtained
by centrifugation at 1,200 × g for 10 min. The
supernatant was sterilized by filtration through a 0.45-µm membrane
filter (Millipore Co.) and stored at
30 °C until used.
Anion-exchange Chromatography--
DE52 (Whatman, Springfield,
UK) anion-exchange chromatography was carried out at 4 °C using a
2.5 × 60-cm column equilibrated with 0.016 M Tris-HCl
buffer, pH 7.7. Elution was performed with a linear gradient of NaCl
(0-0.3 M) in the Tris-HCl buffer at a flow rate of 10 ml/h, and 8.5-ml fractions were collected.
Affinity Chromatography on Procion Red-Agarose--
Procion
red-agarose (Life Technologies, Inc.) was packed in a column (1.2 × 6-cm) and was equilibrated with 0.016 M Tris-HCl buffer,
pH 7.7. Samples were dialyzed against the same buffer and applied to
the Procion red-agarose column. The column was first washed with 60 ml
of starting buffer, and then elution was performed with a linear
gradient of NaCl (0-1.5 M) in the Tris-HCl buffer at a
flow rate of 10 ml/h, and 6-ml fractions were collected.
Size Exclusion HPLC--
A sample was concentrated to 0.5 ml and
applied to a size exclusion HPLC column (G3000SW, 0.78 × 30-cm,
Toso, Tokyo, Japan) equilibrated with PBS. Chromatography was performed
at a flow rate of 1.0 ml/min, and fractions of 0.7 ml were collected.
Reverse Phase HPLC--
A sample was concentrated to 0.5 ml and
applied to an Cosmosil 5C18 column (4.6 × 25-cm, Nacalai Tesque). Elution was performed with a linear gradient of
0-70% acetonitrile in 0.1% trifluoroacetic acid at 25 °C and a
flow rate of 0.7 ml/min, and 0.7-ml fractions were collected.
Amino Acid Sequence Analysis--
The amino acid sequence was
determined by automated Edman degradation on a gas-phase protein
microsequencer (ABI470A, Perkin-Elmer, Foster City, CA).
Antisera--
Female Lewis rats were immunized twice at a
monthly interval in both hind footpads with a total of 0.2 ml of a 1:1
emulsion of the purified ECF-L (10 µg) in PBS and H37Ra adjuvant
(Difco Laboratories, Detroit, MI). 2 weeks after the second
immunization, they were bled, and the serum was separated.
Establishment of a monoclonal antibody (mAb) to ECF-L was carried out
according to a method described previously (14) with modifications. In short, female Lewis rats were immunized twice with the purified ECF-L
(10 µg) emulsified in H37Ra adjuvant. The spleens were removed 2 weeks after the last immunization and were hybridized to Sp2/0. A clone
(E3.1) was selected, and the mAb was purified from the culture
supernatant of hybridomas by gel chromatography on Sephacryl S300
(Amersham Pharmacia Biotech) for experimental use. The isotype of E3.1
was determined as IgM by a kit (Binding Site, Birmingham, U. K.).
Construction of the cDNA Library--
The total RNA of bone
marrow cells was isolated by the guanidine
isothiocyanate/CsCl2 method (15). Poly(A)+ RNA
was selected by two passages over oligo(dT)-cellulose (Amersham Pharmacia Biotech). cDNA synthesis was performed using a cDNA synthesis kit (Amersham Pharmacia Biotech). The cDNAs were cloned into the EcoRI site of
gt11 vector (Promega Biotec,
Madison, WI). Viral DNA was then packaged in vitro by means
of Gigapack (Stratagene, La Jolla, CA).
Isolation and Analysis of a cDNA Clone--
Independent
recombinant clones (2 × 105) were screened using
1,000 × diluted anti-ECF-L polyclonal antibody as an antibody probe. Clones reacting with the antibody were isolated from the cDNA library and subcloned into Bluescript SK
(Stratagene).
Nested deletions were prepared by using a nested deletion kit (Amersham Pharmacia Biotech). The sequences of suitable clones were determined by
the dideoxy chain termination method using an automated DNA sequencer
(ABI310, Perkin-Elmer).
Construction of the Baculovirus Transfer Vector and Generation of
the Recombinant Virus--
A BamHI site was created 6 bp
upstream of the translation initiation codon and an EcoRI
site 6 bp downstream of the stop codon to obtain a full-length cDNA
by polymerase chain reaction, and the cDNA was digested with the
BamHI and EcoRI. The
BamHI-EcoRI fragment was then ligated to pVL1393
(Invitrogen). The recombinant pVL construct was co-transfected into
Spodoptera frugiperda Sf21 insect cells with a
modified Autographa californica nuclear polyhedrosis virus
DNA (BaculoPlus, Pharmingen), and the resultant viral pool was
collected 4 days later.
Preparation of Recombinant Proteins--
Sf21 insect
cells were cultured in Grace medium supplemented with 10% fetal bovine
serum (Life Technologies, Inc.) at 27 °C. To produce recombinant
proteins, Sf21 cells seeded at a density of 106
cells/ml were infected with the recombinant virus. The cells were
harvested 96 h after infection, washed with a solution of 0.15 M NaCl in 0.02 M phosphate buffer, pH 7.4, homogenized in a Tris-HCl, pH 7.6, and centrifuged at 10,000 × g for 20 min. Recombinant ECF-L was purified from the
supernatant using DE52, Procion red-agarose, G3000SW, and
5C18 columns following the same steps as for
the purification of natural ECF-L from the culture supernatant of splenocytes.
SDS-PAGE and Immunoblot--
SDS-PAGE was performed on 10%
polyacrylamide gel by using the discontinuous buffer system of Laemmli
(16) with prestained Rainbow protein molecular weight markers (Amersham
Pharmacia Biotech). Western blotting onto a nitrocellulose filter
(Amersham Pharmacia Biotech) was performed as described (17). Blots
were immunostained with 1,000 × diluted anti-ECF-L antiserum and
2,000 × diluted alkaline phosphatase-labeled goat anti-rat IgG
(EY Laboratories, San Mateo, CA). Antibodies were detected with
substrate containing 0.05 mg/ml 5-bromo-4-chloro-3-indolyl phosphate,
0.1 mg/ml nitro blue tetrazolium, and 4 mM
MgCl2 in 100 mM Tris-HCl, pH 9.6.
Northern Blot Analysis--
Total RNA from each organ was
isolated using Isogen (Nippon Gene, Tokyo, Japan) from female C57BL/6
mice infected with 100 tetrathyridiae of M. corti 2 weeks
earlier. 10 µg of total RNA from each organ was electrophoresed in
1% formaldehyde-agarose gel in MOPS and transferred onto a Hybond-N
membrane (Amersham Pharmacia Biotech). After prehybridization for
3 h in 50% formamide, 5 × Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA at 65 °C, blots were hybridized
with random primed 32P-labeled probes for 16 h under
identical conditions. Filters were washed three times with 1 × SSC containing 0.1% SDS at 65 °C and then exposed to x-ray film
(BioMax, Eastman Kodak, Rochester, New York). 32P-Labeled
polymerase chain reaction fragments of ECF-L and mouse glyceraldehyde-3-phosphate-dehydrogenase cDNAs were used for probes.
Analysis of Interaction with Chitins--
Chitinase activity was
measured by a chromogenic assay using 200 mM
p-nitrophenyl
-D-N,N',N"-triacetylchitotriose
(Sigma) in 0.05 M phosphate buffer, pH 6.8, as the
substrate. Chitinase from Serratia marcescens (Sigma) was
used as a positive control. Chitin bead (Life Technologies, Inc.)
chromatography (1.0 × 3.3-cm column) was performed with PBS at a
flow rate of 3.0 ml/h, and 0.6-ml fractions were collected.
 |
RESULTS |
Purification of ECF-L--
For purification of ECF-L protein, the
medium conditioned by spleen cells obtained from S. japonicum-infected mice was concentrated, dialyzed against
Tris-HCl buffer, and applied to a DE52 anion-exchange column. ECF
activity was eluted at around the 0.15 M NaCl region of the
gradient (Fig. 1A). Active
fractions were pooled, concentrated by ultrafiltration, dialyzed
against Tris-HCl buffer, and then applied to the Procion red-agarose
affinity column. Elution profiles are shown in Fig. 1B. The
major ECF activity was eluted at around 0.5 M NaCl.
ECF-positive fractions were pooled, concentrated, and chromatographed
by G3000SW HPLC (Fig. 1C). ECF-positive fractions were
pooled and purified further on a reverse phase HPLC column (Fig.
1D). A single absorbance peak at 230 nm coincided with the peak of ECF activity. The purified ECF-L showed homogeneity on SDS-PAGE
analysis (Fig. 1E) with a molecular mass of 43-kDa, and the
specific eosinophil chemotactic activity was approximately 100 times
that of the crude supernatant (Fig. 1F).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
Purification of ECF-L. A-D,
purification of ECF-L from the culture supernatant of splenocytes of
mice infected with S. japonicum. ECF-L was purified by a
serial combination of anion-exchange chromatography on DE52
(A), affinity chromatography on Procion red-agarose
(B), HPLC on G3000SW (C), and reverse phase HPLC
on 5C18 (D). The lower
panels represent absorbance at 280 nm (A and
B) or 230 nm (C and D) (solid
lines) of each fraction or NaCl (A and B) or
acetonitrile (D) gradient (dashed lines). The
upper panels (closed columns) show the eosinophil
chemotactic activity of each fraction. E, SDS-PAGE analysis
of the purified ECF-L. Lane 1, purified ECF-L (2 µg);
lane 2, molecular weight standards. Samples were denatured
in Laemmli buffer with 2-mercaptoethanol and analyzed on 12.5%
SDS-polyacrylamide gels. The gel was stained by a silver staining kit.
F, comparison of ECF activity between crude conditioned
medium of splenocytes (closed circles) and purified ECF-L
(open circles). The data represent the mean ± S.E. of
four samples.
|
|
Isolation of ECF-L cDNA--
The cDNA library of bone
marrow of mice was screened with an anti-ECF-L polyclonal antibody or
mAb E3.1b. Of approximately 1,000,000 plaques screened, one plaque was
found to be positive. The positive clone was picked and purified
through three successive rounds of replating antibody screening. The
insert was purified and subcloned into Bluescript SK
. As shown in
Fig. 2, sequence analysis revealed that
the cDNA was 1,506 bp long with a 1,197-bp open reading frame that
could encode a protein 397 amino acids long. The putative amino acid
sequence included the NH2-terminal 21-amino acid
endoplasmic reticulum signal peptide followed immediately by the
NH2-terminal sequence of natural ECF-L as determined by a
protein microsequencer (YQLMXYYTSWAKDRPIEG). The molecular
mass of mature ECF-L, calculated from the deduced amino acid sequence, was 42,370 Da. This value is close to the one determined experimentally by SDS-PAGE (Fig. 1E). The calculated isoelectric point (pI
5.3) was somewhat higher than that determined experimentally (pI 3.6) by isoelectric focusing (11). The sequence does not contain any
consensus N-linked glycosylation sites (NXS,
NXT) (18). In addition, the mRNA contains an
approximately 300-bp-long untranslated region with a polyadenylation
signal (AAUAAA) toward the 3'-end.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 2.
Nucleotide sequence and deduced amino acid
sequence of ECF-L. The hydrophobic leader sequence is
underlined with dots. The matched residues of the
deduced amino acid sequence and the NH2-terminal amino acid
sequence of natural ECF-L are underlined. The
polyadenylation signal is indicated in bold lettering. The
reverse type denotes the highly conserved residues
(conserved in more than 80% of 20 representative chitinases or
chitinase family proteins as shown in Fig. 5). The reverse
type with asterisks indicates the completely conserved
residues in the 20 representative chitinases and chitinase family
proteins. Boxed letters denote the specific amino acid
substitution in ECF-L of highly conserved residues (conserved in more
than 80% of the 20 chitinases or chitinase family proteins).
Double underlining denotes a highly conserved region that
includes amino acids essential for chitinase activity.
Numbers indicate the nucleotide position. The sequence data
have been deposited in the DDBJ data base.
|
|
Recombinant ECF-L was prepared by a baculovirus expression system and
purified by a combination of anion-exchange chromatography on DE52,
affinity chromatography on Procion red-agarose, gel chromatography on
G3000SW, and reverse phase HPLC. The purified recombinant protein showed a single band on SDS-PAGE analysis with a molecular mass of 43 kDa (data not shown). The ECF activity of the recombinant ECF-L was
comparable with that of the natural ECF-L (Fig.
3A) and was completely
inhibited by mAb to ECF-L (E3.1b) as well as natural ECF-L (Fig.
3B).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 3.
Characterization of recombinant ECF-L.
A, comparison of recombinant ECF-L with natural ECF-L.
Eosinophil chemotactic activity of crude (closed circles) or
purified (open circles) ECF-L is shown. Each point
represents the mean ± S.E. of four samples. B,
specific inhibition of eosinophil chemotaxis of ECF-L by mAb. Purified
natural (open circles) or recombinant (closed
circles) ECF-L was preincubated with anti-ECF-L mAb at 20 °C
for 20 min and examined for eosinophil chemotaxis. An inhibition study
of eosinophil chemotaxis of natural (open squares) or
recombinant (closed squares) ECF-L for control mAb was also
performed under the same experimental conditions.
|
|
We next examined the cellular specificity of ECF-L as a
chemoattractant. Because the optimum chemotactic activity of RANTES, GRO, and MCP-1 was achieved at 10-8 M in our
assay system, the same molar concentration of ECF-L was employed for
the comparative chemotaxis assays. As shown in Fig.
4, both natural and recombinant ECF-L
exhibited chemotactic activity for T lymphocytes and bone marrow cells
as well as for eosinophils. Most of the migrated bone marrow cells in
the membrane showed PMN-like features with segmented nuclei. In
contrast, ECF-L exhibited a limited chemotactic activity for mature
neutrophils and no detectable chemotactic activity for macrophages.
This cellular specificity of ECF-L was similar to that of RANTES. On
the other hand, GRO showed chemotactic activity for mature neutrophils
but not for bone marrow cells. mAb to ECF-L (ECF-3) could inhibit most
of the chemotactic activity of ECF-L for eosinophils, T lymphocytes, and bone marrow cells but not the chemotactic activities of RANTES, GRO, or MCP-1.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 4.
Cellular specificity of ECF-L as a
chemoattractant in vitro. The chemotactic
activity of recombinant ECF-L (rECF-L) or natural ECF-L
(ECF-L) was examined in the absence (closed
column) or presence (open columns) of 20 µg/ml
anti-ECF-L mAb (ECF3). ECF-L was preincubated with anti-ECF-L mAb at
20 °C for 20 min and examined for chemotactic activity. The
chemotactic activity of ECF-L for eosinophils (A),
neutrophils (B), macrophages (C), T lymphocytes
(D), and bone marrow cells (E) was examined.
RANTES was used for the positive control of chemotactic activity for
eosinophils, T lymphocytes, or bone marrow cells, GRO for neutrophils,
and MCP-1 for macrophages at 10 8 M,
respectively. PBS was used for the negative control.
|
|
To examine whether ECF-L could induce eosinophils to extravasate into
the inflammatory site, recombinant ECF-L was injected intradermally on
the back of mice infected with M. corti. As shown in Fig.
5, large numbers of permeated eosinophils
were observed at the site where ECF-L was injected. 90 ± 7%
of the migrated leukocytes outside the blood vessel were eosinophilic
when 29 ± 4% of all leukocytes in the blood were eosinophils in
the treated mice. The number of migrated eosinophils increased
dose-dependently with ECF-L. The increase in eosinophil
migration was observed at as low as 5 × 10
8
M (1 pmol).

View larger version (106K):
[in this window]
[in a new window]
|
Fig. 5.
Extravasation of eosinophils induced by
ECF-L. Typical pictures of extravasated eosinophils in the skin of
M. corti-infected mice (3 weeks postinfection) injected with
25 µl of PBS (A) or 4 × 10 8
M (B), 2 × 10 7 M
(C), or 10 6 M (D) of
recombinant ECF-L. 90 ± 7% of the infiltrated leukocytes are
eosinophils with red colored large granules.
|
|
Production of ECF-L in a Parasitic Infection--
Kinetics of the
ECF-L production by splenocytes were examined in M. corti-infected mice. As shown in Fig.
6A, production of eosinophil
chemotactic activity by splenocytes was detectable as early as 2 weeks
postinfection by Western blot analysis in an antigen-specific manner
and increased with time. The amount of ECF-L detected was correlated
with the eosinophil chemotactic activity of the culture supernatant of
splenocytes (Fig. 6B). When the ECF-L mRNA expression of
each organ was examined at 2 weeks after M. corti infection,
high level mRNA expression was detected in spleen, bone marrow,
lung, and heart (Fig. 6C). Lower levels of mRNA were
also detected in liver, thymus, and small intestine. A message for
ECF-L was generally undetectable in normal mice by Northern blot
analysis, whereas a low level of mRNA was detected by reverse
transcription-polymerase chain reaction in bone marrow, spleen, and
thymus in normal mice (data not shown). Nucleotide sequences of the
reverse transcription-polymerase chain reaction products (1-1,195)
from the liver, spleen, and bone marrow mRNA of ddY mouse were
identical to the sequence of the isolated cDNA clone from the
library (Fig. 2).

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 6.
Production of ECF-L in M. corti
infection. A, splenocytes at 0 (0 W),
2 (2 W) or 4 (4 W) weeks after infection with
M. corti were incubated without (0) or with 10 or
100 µg/ml M. corti larval antigen. Production of ECF-L was
examined by Western blot analysis. B, splenocytes at 0, 2, or 4 weeks after infection with M. corti were incubated
without (closed column) or with 10 (gray column)
or 100 (open column) µg/ml M. corti larval
antigen. Supernatants were examined for eosinophil chemotactic
activity. C, Northern blot analysis of ECF-L mRNA
expression. Liver (lane 1), spleen (lane 2),
thymus (lane 3), brain (lane 4), bone marrow
(lane 5), lung (lane 6), heart (lane
7), kidney (lane 8), or small intestine (lane
9) from M. corti-infected mice at 2 weeks after
infection was examined for ECF-L or GAPDH mRNA expression. The
position of rRNA is indicated on the left.
|
|
Sequence Homology with Other Proteins--
A comprehensive search
of GenBank or EMBL nucleic acid data bases revealed that ECF-L
possesses significant homology with prokaryotic chitinases, class III
plant chitinases, fungus chitinase, insect and nematode chitinase, and
chitinase family proteins distributed in vertebrate animals. An optimal
alignment of 20 representative chitinases or chitinase family proteins
was performed using the multiple sequence alignment program, Clustal X. 49 residues are highly conserved in more than 80% of the 20 representative chitinase family proteins, and 13 residues are
completely conserved in all chitinase family proteins including ECF-L
(Fig. 2). ECF-L retains 44 residues (90%) out of the 49 highly
conserved. Fig. 7 shows an alignment of a
conservative region where the catalytic center of the chitinases is
located (19). Aspartic acid, essential for catalytic activity (19), is
conserved in all of the chitinases and chitinase family proteins other
than ECF-L. Although the other essential acid for catalytic activity
(19), glutamic acid, is conserved in all of the chitinases, it is
generally replaced by leucine or isoleucine in chitinase family
proteins that have no chitinolytic activity (20-25). In ECF-L, both
the glutamic acid and the aspartic acid are replaced, by glutamine and
asparagine, respectively.

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 7.
Aligned ECF-L amino acid sequence of a highly
conserved region with 19 chitinase family proteins. The deduced
amino acid sequence of ECF-L is aligned with the sequences of human
chondrocyte protein YKL-39 (GenBankTM accession no.
U49835), human cartilage gp-39 (M80927), human oviductal glycoprotein
(U09550), Mesocricetu auratus oviductin (U15048), Mus
musculus BRP39 protein (X93035), Sus scrofa
heparin-binding glycoprotein (Z47803), human chitotriosidase (U29615),
Chelonus sp. venom chitinase (U10422), Aedes
aegypti chitinase (AF026492), Anopheles gambiae
chitinase (AF008575), Manduca sexta chitinase (U02270),
Brugia malay chitinase (M73689), Oncocerca volvis
chitinase (L42021), Nicotiana tabacum chitinase class V
(X77110), Entoamoeba histritica chitinase (U78319),
Aphanocladium album chitinase (X64104),
Acanthocheilonema viteae chitinase (L42010),
Stemotrophomonas maltophilia chitinase (AF014950),
Serratia marcescens chitinase A (Z36294), and Bacillus
circulans chitinase A1 (M57601). Boxed letters show
chitinases that possess chitinolytic activity. The reverse
type residues indicate amino acids that are identical in at least
50% of the members of this group of proteins. The asterisk
and double asterisk represent the positions of aspartic acid
and glutamic acid essential for proton donation in hydrolysis (19),
respectively.
|
|
ECF-L possesses the CXC consensus sequence near the
NH2 terminus which is typical of CXC chemokines.
However, for ECF-L with CC chemokines or CXC chemokines
(Fig. 8) poor alignments including for
second and third cysteine residues were obtained.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 8.
Aligned ECF-L amino acid sequences around the
CXC sequence with CXC or CC chemokine
family proteins. The deduced amino acid sequence of ECF-L is
aligned with interleukin (IL-8; GenBank accession no. Y00787),
lipopolysaccharide-induced CXC chemokine (LIX; U27267),
MIP-2 (X53798), murine homolog of a human GRO (J04596), mouse monokine
induced by -interferon (MIG; M34815), pre-B cell growth-stimulating
factor (PBSF; D21072), murine macrophage interferon-inducible protein
10 (IP-10; M33266), eotaxin (U40672), MIP-1 (X12531), MIP-1
(M35590), MIP-1 (U49513), C10 (M58004), RANTES (S37648), and MCP-3
(S71251). Dashes represent gaps that have been introduced to
facilitate alignment. The shaded residues indicate amino
acids that are identical in at least three of the members of this group
of proteins. Cysteins are indicated with inverted
letters.
|
|
Analysis of Interaction with Chitins--
We could not detect any
chitinase activity in purified ECF-L at any concentration up to 0.5 mg/ml. On the other hand, natural ECF-L eluted far behind (162%) the
bed volume of the chitin column, whereas bovine serum albumin or other
unrelated proteins eluted at 47% of the bed volume.
 |
DISCUSSION |
In this paper, we described the purification, cDNA cloning,
and molecular characterization of a novel eosinophil chemotactic cytokine, ECF-L, which is produced in parasitic infections upon stimulation of specific antigens. Comparisons of the inferred protein
sequence against all of the sequences in the GenBank or EMBL data base
revealed a high degree of similarity to chitinase belonging to family
18 of glycosyl hydrolases (26) and vertebrate chitinase family proteins
without chitinase activity (20-25). Sequence alignments revealed that
ECF-L is an independent molecule different from other known ECF
cytokines such as interleukin-5 (27), RANTES (28), eotaxin (29), or
ecalectin (30).
Chitinases catalyze the hydrolysis of
-1,4-N-acetylglucoside linkages in chitin and
chitodextrins and are widely distributed among a variety of species
such as bacteria, fungi, nematodes, plants, insects, and vertebrates.
In plants, chitinases/lysozymes themselves likely form part of innate
immune system important for host defense against invading pathogenic
bacteria and fungi (31). Insect or nematode chitinases are likely
essential to certain life cycle events such as molting of the larval
exoskeleton or casting of the egg shell (32). Similarly, protozoans
increase chitin synthesis (33) and chitinase activity (34) during
encystation. On the other hand, proteins of the so-called chitinase
family are distributed in mammals and have no detectable chitinolytic activity (20-25). The actual physiological roles of the mammalian chitinase family proteins remain to be clarified. The present study has
revealed a significant physiological role for a novel chitinase family
protein in mammals.
Eosinophils contain many cytotoxic mediators including eosinophil
peroxidase, major basic protein, and eosinophil cationic protein.
Eosinophils have been observed to be degranulated accompanying eosinophil infiltration around the tissue-invasive stages of helminth infection. In vitro experiments have shown that eosinophils
possess helminthotoxic activity against the larvae of parasites of
Schistosoma (35), Brugia (36),
Trichinella (37), and Strongyloides (38). Production of ECF-L at local sites would contribute to the triggering of the influx of eosinophils that act as effectors of parasite killing.
Thus, ECF-L may have evolved from a chitinase as an immune molecule
from invading parasites by means of accumulating eosinophils followed
by secreting toxic substances rather than directly digesting parasites.
Chitinase-related proteins of vertebrates share relatively weak amino
acid sequence homology with chitinases as a whole. To elucidate the
possible function of the conserved residues of ECF-L, the alignment of
ECF-L and 19 sequences of representative chitinase-related proteins was
performed (Figs. 2 and 5). 13% of the amino acids (49 residues) were
highly conserved in more than 80% of the representative chitinase or
chitinase family proteins. The ratio of aromatic amino acids (Phe, Tyr,
Trp) in the highly conserved residues (34.7%) is relatively high
compared with those among all of the residues (14.8%) of ECF-L.
Glycine was also prominent in the conserved residues (20.4%) compared
with that in total ECF-L (8.5%).
The tertiary structures of some chitinase proteins have been resolved:
these proteins all share the feature of a (
)8 barrel topology (39, 40). Based on the amino acid sequence homology, the
locations of these conserved amino acids of ECF-L are assumed by
analogy. Some highly conserved aromatic amino acids of ECF-L (Tyr-6,
Trp-10, Phe-37, Tyr-246, Trp-339) likely form hydrophobic clusters in
the active cleft, and two (Phe-37, Trp-339) of these residues form a
cis-peptide bond that is assumed to play a key role in
substrate recognition. In terms of position, the glycine residues
(Gly-76 and Gly-77) are highly conserved; they likely locate at the end
of the third
-strand where a conserved phenylalanine (Phe-37) is
closely located. All but one of the highly conserved glycine residues
are also located in the
-strand or 
-loops, indicating that
replacement by other residues may not be permitted to avoid a steric
hindrance. ECF-L shares the highly conserved aromatic amino acids and
glycines that form a substrate recognition site, and this fact suggests
that ECF-L retains a similar ability for the recognition or
conformational change of chitin-related carbohydrates. In fact, elution
of ECF-L from the chitin beads column clearly took longer than
estimated probably because of the interaction with chitins. As for the
carbohydrate recognition of ECF, human ecalectin that binds to
carbohydrates (
-galactosides) possesses ECF activity (30). The
ability to recognize carbohydrate may be another aspect of ECF-L in the
protective immunity against parasitic infections because chitin-related
carbohydrates are an important component of the exoskeleton of larvae
and egg shells in nematodes (32).
As for the catalytic activity of chitinases, a site-directed
mutagenesis study of chitinase A1 from Bacillus circulans
showed that artificial mutation of either glutamic acid at position 204 (Glu
Gln or aspartic acid at position 200 (Asp
to Asn) resulted in a remarkable loss of catalytic activity (19), indicating that the
carbonic acids of both residues are essential for proton donation in
hydrolysis. In ECF-L, both the essential glutamic acid (corresponding
location in ECF-L: Gln-119) and aspartic acid (corresponding location
in ECF-L: Asn-115) are modulated in the natural protein, explaining the
undetectable level of chitinolytic activity. In other vertebrate
chitinase family proteins that have no catalytic activity, glutamic
acid is replaced by a similar sized hydrophobic side chain such as
leucine in synovial protein (21) and oviductal glycoprotein (22), or
with isoleucine, such as in major secreted protein of human articular
chondrocytes (20) and heparin-binding glycoprotein (25). On the other
hand, the essential aspartic acid is generally conserved. Thus ECF-L possesses a unique blocking form of two essential carbonic acids in
contrast to other vertebrate chitinase family proteins, and this fact
may suggest a unique function of ECF-L among chitinase family proteins
without chitinase activity.
It has been proposed that blocking parasite-derived chitinases could
block the transmission of malaria (41) by inhibiting the chitinase
activity needed for the penetration of the peritrophic membrane in
anopheline mosquitoes. Similarly, microfilarial stage-specific chitinase has been shown to be a candidate antigen for a
transmission-blocking vaccine against filariasis (42). The sequence
similarity between the chitinase family proteins of the host molecules
and parasite-derived chitinases suggests some restriction in the use of
chitinases as vaccine molecules.
ECF-L possesses a CXC sequence near the NH2
terminus of the mature molecule. The CXC or CC sequence is a
typical motif shared in many chemokine family proteins but not in other
chitinase family proteins. Amino acid sequence alignments of ECF-L with
CXC or CC chemokines revealed no sequence similarity even
around the CXC sequence (Fig. 7) where the critical receptor
binding region exists (43, 44). The other two cysteine residues
conserved in all of the chemokines are not found in ECF-L. Moreover,
the tertiary structure of interleukin-8, a CXC chemokine,
exhibits topography similar to that of the
1/
2 domains of the
human class I histocompatibility antigen HLA-A2 (45) and to share no
similarity with chitinases (39, 40). This would consistently indicate that ECF-L is an independent molecule, not one of these chemokines.
We found that ECF-L attracts not only eosinophils but also T
lymphocytes and bone marrow PMNs. ECF-L possesses a specificity similar
to RANTES as a chemoattractant in that it attracts CD4+
memory T lymphocytes (46), eosinophils, and bone marrow cells (Fig. 4).
This indicates that the receptor(s) for ECF-L are related to that for
RANTES (47, 48). The specific inhibitory effect of anti-ECF-L mAb is
likely understood in terms of the steric hindrance that resulted in the
obstruction of chemotactic epitope(s) on ECF-L.
Recent evidence suggests that eosinophils bind to vascular endothelial
cells, and their transendothelial migrations are mediated by
interactions of various adhesion molecules and their ligand molecules
(49). ECFs produced in the inflammatory site would play a critical role
in the exit of eosinophils from vasculature and their attraction to the
inflammatory site. In the present study, we showed that ECF-L could
induce the specific extravasation of eosinophils into the injected site
at as low as 1 pmol. This result suggests that eosinophil-specific
transendothelial migration could be caused by ECF-L when an appropriate
amount of ECF-L is produced outside the blood vessel. The discrepancy
in the cellular specificity of ECF-L in in vivo (Fig. 5) and
in vitro (Fig. 4) studies would be the result of complicated
mechanisms of transendothelial processes in vivo including
the effects of adhesion molecules (49).
With regard to whether enough ECF-L is generated locally to cause
tissue eosinophilia around the larvae, little evidence of this is
presently available. Expression of ECF-L mRNA was not limited to
the liver where the M. corti larvae locate. So far as we
could ascertain, spleen, bone marrow, lung, and heart are the dominant
organs of production of mRNA encoding ECF-L. Western blot and flow
cytometric analysis also indicate that ECF-L molecules locate on some
populations of bone barrow cells (data not shown). Furthermore, ECF-L
exhibits chemotactic activity for bone marrow PMN (Fig. 4E).
These results together with our previous finding that ECF-L could
change the chemotactic reactivity of immature eosinophils located in
bone marrow (10) suggests a major role for ECF-L in the priming of
naive eosinophils or neutrophils. Alternatively, antigen-specific
production of ECF-L by splenocytes and chemotactic reactivity of ECF-L
for bone marrow cells would support the idea that the spleen is the
site of maturation of immature eosinophils (9) and neutrophils, and
thus ECF-L contributes to the recruitment of immature PMNs to this site.
Several eosinophil chemotactic cytokines have been shown to have
multiple functions (27, 50). In addition to their role in the
recruitment of eosinophils from the site where PMNs are differentiated
to the inflammatory site and to their priming effects, ECF-L may
participate in the removal of excess eosinophils from the circulation
to spleen or bone marrow where they can be treated and/or reused. The
possible novel functions of ECF-L remain to be clarified.
 |
ACKNOWLEDGEMENTS |
We are grateful to Professors Y. Nawa
(Miyazaki Medical College) and A. Ishii (Jichi Medical School) for
valuable help and encouragement, and we acknowledge the expertise of E. Ohno (Miyazaki Medical College), Y. Taoka, K. Ishii, and N. Mori
(Tokushima University). We also thank Drs. M. Harada (Kagawa Medical
University) and S. Imai (Tokyo Medical and Dental University) for
helpful discussions.
 |
FOOTNOTES |
*
This work was supported in part by Grants 06670260, 09309010, and 10670229 from the Ministry of Education, Science, Sports, and Culture, Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence reported in this paper has been submitted
to the DDBJ/GenBankTM/EBI Data Bank with accession number
D87757.
To whom correspondence should be addressed. Tel.: 88-656-7261; Fax:
88-656-7298; E-mail: ohashi@ias.tokushima-u.ac.jp.
 |
ABBREVIATIONS |
The abbreviations used are:
ECF(s), eosinophil
chemotactic factor(s);
ECF-L, splenocyte-derived ECF;
PBS, phosphate-buffered saline;
FBS, fetal bovine serum;
RANTES, regulated
on activation normal T cell expressed;
GRO, growth-related oncogene;
MCP, monocyte chemoattractant protein;
HPLC, high performance liquid
chromatography;
mAb, monoclonal antibody;
bp, base pair;
PAGE, polyacrylamide gel electrophoresis;
MOPS, 4-morpholinepropanesulfic
acid;
MIP, macrophage inflammatory protein;
PMN, polymorphonuclear
leukocyte.
 |
REFERENCESs |
| 1.
|
Boros, D. L.,
and Warren, K. S.
(1970)
J. Exp. Med.
132,
488-507[Abstract]
|
| 2.
|
Warren, K. S.,
Boros, D. L.,
Hang, L. M.,
and Mahmoud, A. A. F.
(1975)
Am. J. Pathol.
80,
279-290[Abstract]
|
| 3.
|
Sugane, K.,
and Oshima, T.
(1982)
Parasite Immunol.
4,
307-318[Medline]
[Order article via Infotrieve]
|
| 4.
|
Todd, K. S., Jr.,
Simon, J.,
and Dipietro, J. A.
(1978)
Lab. Anim.
12,
51-53[Abstract/Free Full Text]
|
| 5.
|
Owhashi, M.,
Kitagawa, K.,
Horii, Y.,
and Ishii, A.
(1994)
Curr. Topics Vet. Res.
1,
37-41
|
| 6.
|
Spry, C. J. F.
(1971)
Cell Tissue Kinet.
4,
351-364[Medline]
[Order article via Infotrieve]
|
| 7.
|
Owhashi, M.,
Maruyama, H.,
and Nawa, Y.
(1996)
Int. J. Parasitol.
26,
705-711[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Maruyama, H.,
Higa, A.,
Asami, M.,
Owhashi, M.,
and Nawa, Y.
(1991)
Exp. Hematol.
19,
77-80[Medline]
[Order article via Infotrieve]
|
| 9.
|
Spry, C. J. F.
(1971)
Cell Tissue Kinet.
4,
365-374[Medline]
[Order article via Infotrieve]
|
| 10.
|
Owhashi, M.,
Arita, H.,
and Niwa, A.
(1998)
Parasitol. Res.
84,
136-138[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Owhashi, M.,
and Nawa, Y.
(1987)
Int. Arch. Allergy Immunol.
83,
290-295
|
| 12.
|
Owhashi, M.,
and Ishii, A.
(1982)
J. Immunol.
129,
2226-2231[Abstract]
|
| 13.
|
Owhashi, M.,
Horii, Y.,
Imai, J.,
Ishii, A.,
and Nawa, Y.
(1986)
Int. Arch. Allergy Immunol.
81,
129-135
|
| 14.
|
Kenigsberg, R. L.,
Elliott, P. J.,
and Cuello, A. C.
(1991)
J. Immunol. Methods
136,
247-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chirgwin, J.,
Przybyla, A.,
MacDonald, R.,
and Rutter, W.
(1979)
Biochemistry
18,
5294-5299[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354[Abstract/Free Full Text]
|
| 18.
|
Hart, G. W.,
Brew, K.,
Grant, G. A.,
Brandshaw, R. A.,
and Lennarz, W. J.
(1979)
J. Biol. Chem.
254,
9747-9753[Free Full Text]
|
| 19.
|
Watanabe, T.,
Kobori, K.,
Miyashita, K.,
Fujii, T.,
Sakai, H.,
Uchida, M.,
and Tanaka, H.
(1993)
J. Biol. Chem.
268,
18567-18572[Abstract/Free Full Text]
|
| 20.
|
Hakala, B. E.,
White, C.,
and Recklies, A. D.
(1993)
J. Biol. Chem.
268,
25803-25810[Abstract/Free Full Text]
|
| 21.
|
Hu, B.,
Trinh, K.,
Figueira, W. F.,
and Price, P. A.
(1996)
J. Biol. Chem.
271,
19415-19420[Abstract/Free Full Text]
|
| 22.
|
Arias, E. B.,
Verhage, H. G.,
and Jaffe, R. C.
(1994)
Biol. Reprod.
51,
685-694[Abstract]
|
| 23.
|
Paquette, Y.,
Merlen, Y.,
Malette, B.,
and Bleau, G.
(1995)
Mol. Reprod. Dev.
42,
388-396[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Morrison, B. W.,
and Leder, P.
(1994)
Oncogene
9,
3417-3426[Medline]
[Order article via Infotrieve]
|
| 25.
|
Shackelton, L. M.,
Mann, D. M.,
and Millis, A. J. T.
(1995)
J. Biol. Chem.
270,
13076-13083[Abstract/Free Full Text]
|
| 26.
|
Henrissat, B.,
and Bairoch, A.
(1993)
Biochem. J.
293,
781-788
|
| 27.
|
Kinashi, T.,
Harada, N.,
Severinson, E.,
Tanabe, T.,
Sideras, P.,
Konishi, M.,
Azuma, C.,
Tominaga, A.,
Bergstedt-Lindqvist, S.,
Takahashi, M.,
Matsuda, F.,
Yaoita, Y.,
Takatsu, K.,
and Honjo, T.
(1986)
Nature
324,
70-73[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Schall, T. J.,
Simpson, N. J.,
and Mak, J. Y.
(1992)
Eur. J. Immunol.
22,
1477-1481[Medline]
[Order article via Infotrieve]
|
| 29.
|
Rothenberg, M. E.,
Luster, A. D.,
and Leder, P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8960-8964[Abstract/Free Full Text]
|
| 30.
|
Matsumoto, R.,
Matsumoto, H.,
Seki, M.,
Hata, M.,
Asano, Y.,
Kanegasaki, S.,
Stevens, R. L.,
and Hirashima, M.
(1998)
J. Biol. Chem.
273,
16976-16984[Abstract/Free Full Text]
|
| 31.
|
Samac, D. A.,
and Shah, D. M.
(1994)
Plant Mol. Biol.
25,
587-596[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Spindler, K. D.,
Spindler-Barth, M.,
and Londershausen, M.
(1990)
Parasitol. Res.
76,
283-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Das, S.,
and Gillin, F. D.
(1991)
Biochem. J.
280,
641-647
|
| 34.
|
Villagomez-Castro, J. C.,
Calvo-Mendez, C.,
and Lopez-Romero, E.
(1992)
Mol. Biochem. Parasitol.
52,
53-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Ramalho-Pinto, F. J.,
McLaren, D. J.,
and Smithers, S. R.
(1978)
J. Exp. Med.
147,
147-156[Abstract/Free Full Text]
|
| 36.
|
Hamann, K. J.,
Gleich, G. J.,
Checkel, J. L.,
Loegering, D. A.,
McCall, J. W.,
and Barker, R. L.
(1990)
J. Immunol.
144,
3166-3173[Abstract]
|
| 37.
|
Bass, D. A.,
and Szejda, P.
(1979)
J. Clin. Invest.
64,
1415-1422
|
| 38.
|
Rotman, H. L.,
Yutanawiboonchai, W.,
Brigandi, R. A.,
Leon, O.,
Gleich, G. J.,
Nolan, T. J.,
Schad, G. A.,
and Abraham, D.
(1996)
Exp. Parasitol.
82,
267-278[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Terwisscha van Scheltinga, A. C.,
Hennig, M.,
and Dijkstra, B. W.
(1996)
J. Mol. Biol.
262,
243-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Perrakis, A.,
Tews, I.,
Dauter, Z.,
Oppenheim, A. B.,
Chet, I.,
Wilson, K. S.,
and Vorgias, C. E.
(1994)
Structure
2,
1169-1180[Medline]
[Order article via Infotrieve]
|
| 41.
|
Huber, M.,
Cabib, E.,
and Miller, L. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
2807-2810[Abstract/Free Full Text]
|
| 42.
|
Fuhrman, J. A.,
Lane, W. S.,
Smith, R. F.,
Piessens, W. F.,
and Perler, F. B.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1548-1552[Abstract/Free Full Text]
|
| 43.
|
Gong, J. H.,
and Clark-Lewis, I.
(1995)
J. Exp. Med.
181,
631-640[Abstract/Free Full Text]
|
| 44.
|
Clark-Lewis, I.,
Schumacher, C.,
Baggiolini, M.,
and Moser, B.
(1991)
J. Biol. Chem.
266,
23128-23134[Abstract/Free Full Text]
|
| 45.
|
Clore, G. M.,
Appella, E.,
Yamada, M.,
Matsushima, K.,
and Gronenborn, A. M.
(1990)
Biochemistry
29,
1689-1696[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Schall, T. J.,
Bacon, K.,
Toy, K. J.,
and Goeddel, D. V.
(1990)
Nature
347,
669-671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Combadiere, C.,
Ahuja, S. K.,
and Murphy, P. M.
(1995)
J. Biol. Chem.
270,
16491-16494[Abstract/Free Full Text]
|
| 48.
|
Raport, C. J.,
Gosling, J.,
Schweickart, V. L.,
Gray, P. W.,
and Charo, I. F.
(1996)
J. Biol. Chem.
271,
17161-17166[Abstract/Free Full Text]
|
| 49.
|
Bochner, B. S,
and Schleimer, R. P.
(1994)
J. Allergy Clin. Immunol.
94,
427-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Coffey, M. J.,
Woffendin, C.,
Phare, S. M.,
Strieter, R. M.,
and Markovitz, D. M.
(1997)
Am. J. Physiol.
272,
L1025-L1029[Abstract/Free Full Text]
|
| 51.
|
Litt, M.
(1963)
Am. J. Pathol.
42,
529-549
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. G. Nair, K. J. Guild, and D. Artis
Novel Effector Molecules in Type 2 Inflammation: Lessons Drawn from Helminth Infection and Allergy
J. Immunol.,
August 1, 2006;
177(3):
1393 - 1399.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Iwashita, S. Morita, Y. Sagiya, and A. Nakanishi
Role of Eosinophil Chemotactic Factor by T Lymphocytes on Airway Hyperresponsiveness in a Murine Model of Allergic Asthma
Am. J. Respir. Cell Mol. Biol.,
July 1, 2006;
35(1):
103 - 109.
[Abstract]
[Full Text]
[PDF]
|
 |
|